Literature DB >> 20458022

Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.

Jeremy S Paikin1, Douglas S Wright, Mark A Crowther, Shamir R Mehta, John W Eikelboom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20458022     DOI： 10.1161/CIRCULATIONAHA.109.924944

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  33 in total

Review 1.  New antiplatelet agents for cardiovascular disease.

Authors:  Doson Chua; Cesilia Nishi
Journal:  CMAJ       Date:  2013-09-09       Impact factor: 8.262

2.  Paradigm shift in anticoagulation therapy, fueling the pump and preventing rhythm crisis.

Authors:  Bright E Ohene; Fei Gao; Yu Jie Zhou
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 3.  Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.

Authors:  Massimo Leggio; Augusto Fusco; Paolo Severi; Mario Lombardi; Elisa Caldarone; Stefania D'Emidio; Massimo Armeni; Daniela Mereu; Maria Grazia Bendini; Andrea Mazza
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

4.  Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding.

Authors:  Antonio Gutierrez; Sunil V Rao
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-06

Review 5.  Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare.

Authors:  Sean Esmonde; Divyesh Sharma; Aaron Peace
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

6.  Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.

Authors:  Peter Bramlage; Alessandro Cuneo; Uwe Zeymer; Matthias Hochadel; Gert Richardt; Sigmund Silber; Jochen Senges; Christoph A Nienaber; Ulrich Tebbe; Karl-Heinz Kuck
Journal:  Clin Res Cardiol       Date:  2013-01-05       Impact factor: 5.460

Review 7.  Mortality Risk Associated with AF in Myocardial Infarction Patients.

Authors:  Rajiv Sankaranarayanan
Journal:  J Atr Fibrillation       Date:  2012-10-06

8.  Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.

Authors:  Matthew W Sherwood; Derek D Cyr; W Schuyler Jones; Richard C Becker; Scott D Berkowitz; Jeffrey B Washam; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Daniel E Singer; Jonathan P Piccini; Christopher C Nessel; Kenneth W Mahaffey; Manesh R Patel
Journal:  JACC Cardiovasc Interv       Date:  2016-08-22       Impact factor: 11.195

Review 9.  Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review.

Authors:  Andrew Krasner; Jonathan L Halperin
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

10.  Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.

Authors:  Valentin Fuster; Deepak L Bhatt; Robert M Califf; Alan D Michelson; Marc S Sabatine; Dominick J Angiolillo; Eric R Bates; David J Cohen; Barry S Coller; Bruce Furie; Jean-Sebastien Hulot; Kenneth G Mann; Jessica L Mega; Kiran Musunuru; Christopher J O'Donnell; Matthew J Price; David J Schneider; Daniel I Simon; Jeffrey I Weitz; Marlene S Williams; W Keith Hoots; Yves D Rosenberg; Ahmed A K Hasan
Journal:  Circulation       Date:  2012-09-25       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.